| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.006 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.007 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.007 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.008 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.097 | 0.008 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.093 | 0.009 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.01 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.01 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.12 | 0.01 |